Zobrazeno 1 - 10
of 532
pro vyhledávání: ''
Autor:
Ulrich Gatzemeier, Michael Boyer, Paolo Paoletti, Salih Emri, Christian Manegold, Claude Denham, Nicholas J. Vogelzang, James J. Rusthoven, James T. Symanowski, Clet Niyikiza, E. Kaukel, Pierre Ruffié
Publikováno v:
Journal of Clinical Oncology. 41:2125-2133
PURPOSE Patients with malignant pleural mesothelioma, a rapidly progressing malignancy with a median survival time of 6 to 9 months, have previously responded poorly to chemotherapy. We conducted a phase III trial to determine whether treatment with
Autor:
Lajos Pusztai, Gabriel N. Hortobagyi, Bryan T. Hennessy, Massimo Cristofanilli, Chafika Mazouni, Fabrice Andre, Attila Tordai, W. Fraser Symmans, Cornelia Liedtke, Marjorie C. Green, Ana M. Gonzalez-Angulo, Kenneth R. Hess, Jaime A. Mejia
Publikováno v:
Journal of Clinical Oncology. 41:1809-1815
PURPOSE Triple-negative breast cancer (TNBC) is defined by the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2) expression. In this study, we compared response to neoadjuvant chemotherap
Publikováno v:
Journal of Clinical Oncology. 41:1331-1338
PURPOSE Immunohistochemistry (IHC) is a newer technique for assessing the estrogen receptor (ER) status of breast cancers, with the potential to overcome many of the shortcomings associated with the traditional ligand-binding assay (LBA). The purpose
Autor:
Tina Pesaran, Jeffrey N. Weitzel, Clarice R. Weinberg, Chi Gao, Susan L. Neuhausen, Eric C. Polley, Alpa V. Patel, Christopher A. Haiman, Christine B. Ambrosone, Celine M. Vachon, Hongyan Huang, Sara Lindstrom, Julie R. Palmer, Esther M. John, Jill S. Dolinsky, Leslie Bernstein, Rohan Gnanaolivu, Allison W. Kurian, Steven N. Hart, Holly LaDuca, Hoda Anton-Culver, Janet E. Olson, Chunling Hu, Amal Yussuf, Song Yao, Nicole L. Larson, Peter Kraft, Jie Na, Fergus J. Couch, Nicholas J. Boddicker, Elena Martinez, Amy Trentham-Dietz, Siddhartha Yadav, Paul W. Auer, Dale R Sandler, Elizabeth C. Chao, Susan M. Domchek, Rachid Karam, Katherine L. Nathanson, James V. Lacey, Jack A. Taylor, David E. Goldgar
Publikováno v:
J Clin Oncol
PURPOSE To determine the contribution of germline pathogenic variants (PVs) in hereditary cancer testing panel genes to invasive lobular carcinoma (ILC) of the breast. MATERIALS AND METHODS The study included 2,999 women with ILC from a population-ba
Autor:
Deepali Jain, Prabhat Singh Malik, Vinod Sharma, Mukesh Yadav, Sachin Khurana, Sushmita Pathy, Deepam Pushpam, Gundu Naresh
Publikováno v:
JCO Global Oncology
PURPOSE The incidence of symptomatic brain metastasis at diagnosis in non–small-cell lung cancer (NSCLC) is 5%-10%, and up to 40% develop during the disease course. There is a paucity of data supporting the role of brain imaging at diagnosis in asy
Autor:
Shannon Gallagher, Jeffrey N. Weitzel, Eric Rosenthal, Placede Tshiaba, Danna F. Grear, Jerry S. Lanchbury, Judy Garber, Susanne Wagner, Benjamin B. Roa, Wade Hedegard, Kathryn Dalton, Mark E. Robson, Johnathan M. Lancaster, Alexander Gutin, Allison W. Kurian, Susan M. Domchek, Elisha Hughes, Thaddeus Judkins, Carol A. Adami, Stephanie Meek
Publikováno v:
JCO Precision Oncology
PURPOSE Screening and prevention decisions for women at increased risk of developing breast cancer depend on genetic and clinical factors to estimate risk and select appropriate interventions. Integration of polygenic risk into clinical breast cancer
Autor:
Koichi Takahashi, Nitin Jain, Guillermo Garcia-Manero, Lucia Masarova, Sa Wang, Courtney D. DiNardo, Naveen Pemmaraju, Guillermo Montalban Bravo, Tapan M. Kadia, Sanam Loghavi, Musa Yilmaz, Ghayas C. Issa, Koji Sasaki, Elias Jabbour, Steven M. Kornblau, Abhishek Maiti, Marina Konopleva, Lianchun Xiao, Curtis Lachowiez, Maria Adeoti, Farhad Ravandi, Michael Andreeff, Nicholas J. Short, Gautam Borthakur, Hagop M. Kantarjian, Naval Daver, Yesid Alvarado
Publikováno v:
J Clin Oncol
PURPOSE Sixty percent of newly diagnosed patients with acute myeloid leukemia (ND-AML) receiving frontline therapy attain a complete response (CR), yet 30%-40% of patients relapse. Relapsed or refractory AML (R/R-AML) remains a particularly adverse p
Autor:
Christopher Sweeney, Eric Winquist, Darren R. Feldman, Ugo De Giorgi, Daniel Y.C. Heng, Silke Gillessen, Michal Chovanec, Jourik A. Gietema, Robert Huddart, Costantine Albany, Fay H. Cafferty, Peter Grimison, Aaron R. Hansen, Carsten Bokemeyer, Karim Fizazi, Jörg Beyer, Christian D. Fankhauser, Nicolas Sauvé, Alexey Tryakin, Torgrim Tandstad, Olof Ståhl, Helene F. S. Negaard, Ronald de Wit, Anja Lorch, Andrea Necchi, David J. Vaughn, Angelika Terbuch, Axel Heidenreich, Cora N. Sternberg, Marcus Hentrich, Xavier Garcia-del-Muro, Gedske Daugaard, Laurence Collette, Jonathan Shamash
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
J Clin Oncol
Gillessen, Silke; Sauvé, Nicolas; Collette, Laurence; Daugaard, Gedske; de Wit, Ronald; Albany, Costantine; Tryakin, Alexey; Fizazi, Karim; Stahl, Olof; Gietema, Jourik A; De Giorgi, Ugo; Cafferty, Fay H; Hansen, Aaron R; Tandstad, Torgrim; Huddart, Robert A; Necchi, Andrea; Sweeney, Christopher J; Garcia-Del-Muro, Xavier; Heng, Daniel Y C; Lorch, Anja; ... (2021). Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(14), pp. 1563-1574. 10.1200/JCO.20.03296
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(14), 1563-+. AMER SOC CLINICAL ONCOLOGY
Universidad de Barcelona
J Clin Oncol
Gillessen, Silke; Sauvé, Nicolas; Collette, Laurence; Daugaard, Gedske; de Wit, Ronald; Albany, Costantine; Tryakin, Alexey; Fizazi, Karim; Stahl, Olof; Gietema, Jourik A; De Giorgi, Ugo; Cafferty, Fay H; Hansen, Aaron R; Tandstad, Torgrim; Huddart, Robert A; Necchi, Andrea; Sweeney, Christopher J; Garcia-Del-Muro, Xavier; Heng, Daniel Y C; Lorch, Anja; ... (2021). Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(14), pp. 1563-1574. 10.1200/JCO.20.03296
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(14), 1563-+. AMER SOC CLINICAL ONCOLOGY
PURPOSE The classification of the International Germ Cell Cancer Collaborative Group (IGCCCG) plays a pivotal role in the management of metastatic germ cell tumors but relies on data of patients treated between 1975 and 1990. MATERIALS AND METHODS Da
Autor:
Michael S. Ewer, Richard D. Gelber, Masakazu Toi, Nicholas Wilcken, Marco Colleoni, Linda Reaby, Susan Dent, Guy Jerusalem, Sebastien Guillaume, Hans-Joachim Lueck, Investigators, Marion Procter, Eleonora Restuccia, Hervé Bonnefoi, Martine Piccart, Young-Hyuck Im, Michael Andersson, Estefania Monturus, Tsang Wu Liu, Evandro de Azambuja, Debora Fumagalli, José Bines, Ian E. Krop, Tadeusz Pienkowski, Emma Clark, Mihaela Sicoe, Christoph Thomssen, Ling Ming Tseng, Giuseppe Viale
Publikováno v:
Journal of Clinical Oncology. 39:1448-1457
PURPOSE APHINITY, at 45 months median follow-up, showed that pertuzumab added to adjuvant trastuzumab and chemotherapy significantly improved invasive disease–free survival (IDFS) (hazard ratio 0.81 [95% CI, 0.66 to 1.00], P = .045) for patients wi
Autor:
Ian Thomas, Richard E. Clark, Jonathan Kell, Lars Kjeldsen, Nigel H. Russell, Brian J. P. Huntly, Robert Kerrin Hills, Alan Kenneth Burnett, Stephen Knapper, Mark Drummond, Sylvie D. Freeman, Mary Frances McMullin, Ruth Spearing
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Burnett, A K, Russell, N H, Hills, R K, Knapper, S, Freeman, S, Huntly, B, Clark, R E, Thomas, I F, Kjeldsen, L, McMullin, M F, Drummond, M, Kell, J & Spearing, R 2020, ' Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses ', Journal of Clinical Oncology : official journal of the American Society of Clinical Oncology, pp. JCO2001170 . https://doi.org/10.1200/JCO.20.01170
Burnett, A K, Russell, N H, Hills, R K, Knapper, S, Freeman, S, Huntly, B, Clark, R E, Thomas, I F, Kjeldsen, L, McMullin, M F, Drummond, M, Kell, J & Spearing, R 2020, ' Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses ', Journal of Clinical Oncology : official journal of the American Society of Clinical Oncology, pp. JCO2001170 . https://doi.org/10.1200/JCO.20.01170
PURPOSE The optimum number of treatment courses for younger patients with acute myeloid leukemia (AML) is uncertain. The United Kingdom National Cancer Research Institute AML17 trial randomly assigned patients who were not high risk to a total of thr